PILA PHARMA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.1 SEK | +2.99% |
|
+10.71% | +93.75% |
| 19/04 | Pila Pharma Appoints New CEO, Chief Scientific Officer | MT |
| 19/04 | Pila Pharma AB Announces Board and Management Appointments | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 109.5 | 49.83 | 38.07 |
| Enterprise Value (EV) 1 | 81.27 | 42.59 | 32.12 |
| P/E ratio | -5.15 x | -1.99 x | -3.4 x |
| Yield | - | - | - |
| Capitalization / Revenue | 15,22,21,540 x | 2,64,95,209 x | 2,60,21,013 x |
| EV / Revenue | 11,30,00,719 x | 2,26,44,356 x | 2,19,51,226 x |
| EV / EBITDA | -8.8 x | -4.8 x | -6.04 x |
| EV / FCF | -1,38,21,181 x | -73,96,710 x | -1,31,58,888 x |
| FCF Yield | -0% | -0% | -0% |
| Price to Book | 3.61 x | 5.98 x | 5.71 x |
| Nbr of stocks (in thousands) | 16,100 | 16,100 | 23,793 |
| Reference price 2 | 6.800 | 3.095 | 1.600 |
| Announcement Date | 23/03/22 | 26/04/23 | 21/03/24 |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | 0.3464 | - | 0.7192 | 1.881 | 1.463 |
| EBITDA 1 | -4.933 | -4.698 | -3.359 | -9.24 | -8.874 | -5.316 |
| EBIT 1 | -4.95 | -4.718 | -3.379 | -9.261 | -8.89 | -6.393 |
| Operating Margin | - | -1,361.9% | - | -1,287.57% | -472.69% | -436.99% |
| Earnings before Tax (EBT) 1 | -5.601 | -8.669 | -6.982 | -17.21 | -26.78 | -9.93 |
| Net income 1 | -5.601 | -8.669 | -6.982 | -17.21 | -26.78 | -9.93 |
| Net margin | - | -2,502.34% | - | -2,392.46% | -1,423.74% | -678.73% |
| EPS | - | - | - | -1.320 | -1.552 | -0.4706 |
| Free Cash Flow | - | - | - | -5.88 | -5.758 | -2.441 |
| FCF margin | - | - | - | -817.59% | -306.14% | -166.82% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 27/05/19 | 29/05/20 | 20/04/21 | 23/03/22 | 26/04/23 | 21/03/24 |
1SEK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 3.42 | 4.07 | 1.41 | 28.2 | 7.24 | 5.95 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | -5.88 | -5.76 | -2.44 |
| ROE (net income / shareholders' equity) | -83.3% | -124% | -128% | -102% | -134% | -123% |
| ROA (Net income/ Total Assets) | -41.7% | -38.7% | -31.7% | -31.1% | -26% | -41.3% |
| Assets 1 | 13.43 | 22.43 | 22 | 55.26 | 102.9 | 24.03 |
| Book Value Per Share | - | - | - | 1.880 | 0.5200 | 0.2800 |
| Cash Flow per Share | - | - | - | 1.750 | 0.3900 | 0.2500 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 27/05/19 | 29/05/20 | 20/04/21 | 23/03/22 | 26/04/23 | 21/03/24 |
1SEK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +93.75% | 7M | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| -5.52% | 206B | |
| +6.17% | 164B | |
| -0.45% | 162B |
- Stock Market
- Equities
- PILA Stock
- Financials Pila Pharma AB
